Sign in
4

Changes in Ownership

Entrada Therapeutics, Inc. Filed Acc 0001689375-23-000015

Chief Financial Officer sold 1,747 shares at an average $10.53 ($18,389)

  • Chief Financial Officer gave up 1,005 shares (to pay taxes)
  • Chief Financial Officer acquired 28,400 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
WENTWORTH KORY JAMES Chief Financial Officer 2023-03-01 Grant or award +28,400 44,909 D: show line 1 in the form
WENTWORTH KORY JAMES Chief Financial Officer 2023-03-02 Shares withheld for taxes −1,005 $11.60 $11,654 43,904 D: show line 2 in the form
WENTWORTH KORY JAMES Chief Financial Officer 2023-03-02 Sale −1,602 $10.46 $16,761 42,302 D: show line 3 in the form
WENTWORTH KORY JAMES Chief Financial Officer 2023-03-02 Sale −145 $11.23 $1,628 42,157 D: show line 4 in the form
Open-market sales · 1,747 sh · avg $10.53 · $18,389

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
WENTWORTH KORY JAMES Chief Financial Officer 2023-03-01 Grant or award · Stock Option (Right to Buy) +43,000 43,000 D: show line 5 in the form
Loading xslF345X03/wf-form4_167787941368609.xml…